Second Genome
is a clinical-stage pharmaceutical company that focuses on developing microbiome-based therapeutics for the treatment of chronical diseases and illness... Read moreSecond Genome
is a clinical-stage pharmaceutical company that focuses on developing microbiome-based therapeutics for the treatment of chronical diseases and illness... Read more
News
May 24, 2022
PR Newswire
Press Release: Second Genome : Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease
Apr 08, 2022
PR Newswire
Press Release: Second Genome : Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1) Activity
Mar 02, 2022
PR Newswire
Press Release: Second Genome : Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration
Feb 24, 2022
FirstWord Pharma
Second Genome: Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)
Feb 18, 2022
StreetInsider
Press Release: Second Genome : Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress
Feb 14, 2022
PR Newswire
Press Release: Second Genome : Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23
Feb 10, 2022
PR Newswire
Press Release: Second Genome : Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)
Dec 21, 2021
FirstWord PHARMA
Second Genome: Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders
Nov 18, 2021
StreetInsider
Press Release: Second Genome : Second Genome Presents Preclinical Data at Crohn's & Colitis Foundation's IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455
Nov 12, 2021
PR Newswire
Press Release: Second Genome : Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy
Second Genome Competitors
1
2
3
4
5
6
7
8
9
10